PCM
INO icon

Poehling Capital Management’s Inovio Pharmaceuticals INO Stock Holding History

Poehling Capital Management’s Portfolio INO Stock Details INO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-8
Closed – – 322
2017
Q4 		$0 Buy
+8
New +$496 ﹤0.01% 288

Other funds holding INO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $26.7B AUM 36.4% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
GC
Guggenheim Capital Chicago, Illinois $12.9B AUM 27.3% 1-Year Est. Return

Poehling Capital Management's INO Position: Q1 2018 in Review

Poehling Capital Management sold out of Inovio Pharmaceuticals (INO) in Q1 2018, closing a stake of 8 shares.

Poehling Capital Management first reported a position in INO in Q4 2017 and held it in 1 quarter. The position peaked at $0 in Q4 2017. 126 funds tracked by Wall St. Rank hold INO as of Q1 2018.

  • Poehling Capital Management reported no remaining Inovio Pharmaceuticals position as of Q1 2018 after selling out during the quarter.
  • Poehling Capital Management sold 8 Inovio Pharmaceuticals shares in Q1 2018.
  • Poehling Capital Management first reported a position in Inovio Pharmaceuticals in Q4 2017 and held it in 1 quarter.
  • Poehling Capital Management's Inovio Pharmaceuticals position peaked at $0 in Q4 2017.
  • 126 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q1 2018.

Based on Poehling Capital Management's 13F filing for Q1 2018, filed 14 May 2018.